BioNotebook: PharmAthene/Theraclone, Orexigen, Optimer/Cubist, Xencor, Exelixis
This article was originally published in Scrip
Executive Summary
PharmAthene ends Theraclone merger; Orexigen proposes $100m note sale; Cubist to cut 177 Optimer jobs; Xencor IPO back on track; and Exelixis exercises commercialization option.